

TRANSCRIPT - SURGEON GENERAL'S (KOOB) AD HOC COMMITTEE ON

"NON-DENTAL HEALTH EFFECTS OF FLUORIDE," APRIL 18 - 19, 1983

TRANSCRIPT OF PROCEEDINGS

NATIONAL INSTITUTES OF HEALTH

Vol. I, Day 1

Pages 1 - 281

Vol. II, Day 11

Pages 282 - 476

MEETING OF
THE FLUORIDE PANEL

ORIGINAL

DAY II

Date: April 19, 1983

Location: Bethesda, Maryland

STENOTECH, INC.

(301) 840-9320

11254 DR. MARX: I don't agree with that.
11255 DR. MARCUS: Well, we voted on this.
11256 DR. MARX: No, we voted on the margin, but
11257 the reason--


11258 DR. MARCUS: So we had different reasons?

11259 DR. MARX: My reason for voting on the low
11260 margin for age zero to nine is because I accept the
11261 cosmetic effects of dental fluorosis as an adverse
11262 health effect. My reason for taking nine as the
11263 cut-off is because I don't see the skeletal
11264 maturations thing as a recognized adverse effect.

11265 The panel was clearly divided on that
11266 issue. I think there were five people who were not
11267 concerned about the levels we are talking about
11268 causing adverse effects on the skeleton and there
11269 were three people who thought that that was a
11270 problem.

11271 DR. COTRUVO: That may fit into the
11272 sentence which says "must decide whether the effects
11273 may be reasonably anticipated, even though not proven
11274 to occur."

11275 DR. MARCUS: Also, I think it is fairly
11276 close to unanimous that we all agreed that dental
11277 fluorosis problem is, in fact, has medical
11278 ramifications. Almost everybody agreed on that. Not



11279 knowing where bone disease begins at any age, what
11280 you are saying is that ^{if} there is something going on in
11281 the teeth, then the likelihood is that there is
11282 something going on in the bone. You don't know that
11283 it is there; you don't know that it is not there.

11284 DR. MARX: Make a proposal so that we can
11285 vote on it.

11286 DR. SHAPIRO: Let's finalize this by asking
11287 for a vote that, up to age nine, we accept twice the
11288 current recommended levels of .7 to 1.2 and that,
11289 above that age, we accept four times the recommended
11290 level as preventing against adverse effects.

11291 Is there any further discussion?

11292 (No response.)

11293 DR. SHAPIRO: All right. All those in
11294 favor?

11295 (There was a show of hands.)

11296 DR. SHAPIRO: All those opposed?

11297 (There was a show of hands.)

11298 DR. SHAPIRO: Two are opposed. Now, let's
11299 have lunch. It is twenty after. I would like to talk
11300 some more about special groups and then extent to
11301 which we can include in our proposal to the PHS and
11302 the EPA a very strong interest in expanding the
11303 amount of data that is available.